A Phase 3 interventional study of AND017 and ESA in Anemia Due to Chronic Kidney Disease, sponsored by Kind Pharmaceuticals LLC. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Kind Pharmaceuticals LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Anemia with a site in China — 33 open to participants now, 42 under way, 8 of them phase 3. Anemia · China.
Among the 115 studies in Anemia with a site in China, this one is the 26th largest by planned enrollment of the 97 interventional ones that give a count, is one of 15 that started in 2025, is one of 22 in phase 3, reaches primary completion later than 20 of the 41 other live ones, and was the 110th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →33 of the 115 studies in Anemia with a site in China are open now. Recruiting first, the newest first:
Guangdong Second Provincial General Hospital · Sites in China
Ages 18–60
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–85
Kind Pharmaceuticals LLC · Sites in China
Ages 18–75
Zhujiang Hospital · Sites in China
Ages 18–70
Guangdong Provincial People's Hospital · Sites in China
Ages 18–75 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 30 · Phase 3 25 · Phase 4 16
First in 1999; this study’s year is marked. 15 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 120 across the 97 interventional studies, 800 across the 18 observational. Of the 45 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 115 have an industry lead sponsor. The 10 most frequent:
Kind Pharmaceuticals LLC is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Kind Pharmaceuticals LLC has 6 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
13 of the studies in Anemia with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07487727Phase 3Kind Pharmaceuticals LLCA Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) | 2026-12-01 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06946394The First Affiliated Hospital of Dalian Medical UniversityUse of Pegmolesatide in Renal Anemia: Efficacy and Safety of Switching to Pegmolesatide in Non-dialysis CKD Patients Treated With rhuEPO or HIF-PHI | 2026-12 |
| NCT07136792Guangdong Provincial People's HospitalA Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI) | 2026-12 |
| NCT07236788China-Japan Friendship HospitalStudy on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency. | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 115 studies in Anemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase III, randomized, open-label, active-controlled study to evaluate the safety and efficacy of AND017 in non-dialysis-dependent (NDD)-CKD patients compared with the active control, ESA treatment
Key Inclusion Criteria:
Prior ESA and hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) treatment
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AND017
Drug: ESA
AND017 capsules administered orally with a starting dose of 8 mg TIW for ESA naive patients or 10 mg TIW for ESA treated patients
ESA injection and dose based on package insert and local practice
Evaluate the efficacy of AND017 compared with the active control in maintaining Hemoglobin (Hb) levels in patients with anemia due to CKD
The mean Hb levels averaged over Week 23-27
Time frame: From Week 23 to Week 27
The percentage of responders
Responder is defined as: for participants with baseline Hb ≥ 9.0 g/dL, mean Hb ≥ 10.0 g/dL and a change from baseline ≥ -1.0 g/dL during Weeks 23-27; for participants with baseline Hb \< 9.0 g/dL, an increase in Hb from baseline ≥ 1.0 g/dL (for) during Weeks 3-27
Time frame: From baseline to Week 27
Percentage of participants that maintained Hb level over target lower limit
Percentage of participants with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-27
Time frame: From Week 5 to Week 27
Maintenance of Hb within 10.0-12.0 g/dL after initial achievement ≥10.0 g/dL during the entire study treatment period
During entire study treatment period, the percentage of participants in which Hb, after first reaching ≥ 10.0 g/dL, is maintained within the target range of 10.0-12.0 g/dL (inclusive)
Time frame: From baseline to Week 53
Incidence of extreme Hb levels of ≥13.0 g/dL or <7.5 g/dL during the entire study treatment period
During the entire study treatment period, the percentage of participants in which Hb is ≥ 13.0 g/dL or \< 7.5 g/dL
Time frame: From baseline to Week 53
Incidence of excessive erythropoiesis
During the entire study treatment period, the percentage of participants with an Hb increase ≥ 1.0 g/dL within any 2-week period and an Hb increase ≥ 2.0 g/dL within any 4-week period respectively
Time frame: From baseline to Week 53
The cumulative incidence of Hb non-response
The cumulative incidence of Hb non-response is defined as Hb \< 10.0 g/dL and an increase from baseline \< 1.0 g/dL averaged over Weeks 5-27.
Time frame: From baseline to Week 27
Mean Hb change from baseline averaged over Weeks 5-27
Mean Hb change from baseline averaged over Weeks 5-27
Time frame: From baseline to Week 27
Mean Hb change from baseline averaged over Weeks 23-27
Mean Hb change from baseline averaged over Weeks 23-27
Time frame: From baseline to Week 27
Mean Hb change from baseline averaged over Weeks 13-17
Mean Hb change from baseline averaged over Weeks 13-17
Time frame: From baseline to Week 17
Mean Hb change from baseline averaged over Weeks 27-53
Mean Hb change from baseline averaged over Weeks 27-53
Time frame: From baseline to Week 53
Mean Hb change from baseline averaged over Weeks 49-53
Mean Hb change from baseline averaged over Weeks 49-53
Time frame: From baseline to Week 53
During the entire treatment period, mean Hb at each visit
During the entire treatment period, mean Hb at each visit
Time frame: From baseline to Week 53
The use of intravenous iron during the entire study treatment period
The percentage of participants that have received intravenous iron during the entire study treatment period
Time frame: From baseline to Week 53
The mean weekly dose of intravenous iron during the entire treatment period
The mean weekly dose of intravenous iron during the entire treatment period
Time frame: From baseline to Week 53
The time to first initiation of intravenous iron during the entire treatment period
The time to first initiation of intravenous iron during the entire treatment period
Time frame: From baseline to Week 53
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's planned 11 months is below that.
Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AND017
Kind Pharmaceuticals LLC